PRINCETON, N.J., Aug. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

PRINCETON, N.J., July 31, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

PRINCETON, N.J., Dec. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

PRINCETON, N.J., Feb. 26, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

The EULAR recommendations for the management of Behçet’s syndrome were first published in 2008, and updated in 2018. Since that time, new evidence has become available, including trials of biologic ...

Both infliximab and adalimumab are safe and effective in achieving remission in patients with severe mucocutaneous Behçet syndrome, with adalimumab demonstrating a quicker response time; both drugs ...

Hatemi, one of the two co-convenors of the EULAR task force behind the revised recommendations, said there had been changes not just to the content but also to the wording of the recommendations to ...

・The trial was evaluating HyBryte in a rare form of cancer with limited treatment options. ・The company also plans to assess whether certain patient groups could still benefit from the therapy. ・Last ...

The Orphan Drug designation was supported by data from an open-label phase 2 trial that included 8 adult patients with mild to moderate Behçet disease and active oral and/or genital ulcers. The Food ...

Hello. I am Hiro, a licensed psychologist.I have an intractable disease called Behcet's disease, and I am attacked daily by ...